The IIFL Securities Report: Buy Piramal Pharma - May 03

IIFL Securities recommends a 'buy' for Piramal Pharma, setting a target price of Rs 160. This represents a potential upside of 4.5% from the current market price of Rs 153.05. The company's strong balance sheet and consistent growth prospects drive this positive outlook. Piramal Pharma has a diversified product portfolio and a presence in over 100 countries, providing a solid foundation for future expansion.

About Piramal Pharma:

Piramal Pharma Limited (formerly Piramal Healthcare Limited) is a global pharmaceutical company headquartered in Mumbai, India. It primarily focuses on the development, manufacturing, and marketing of complex generic injectables, active pharmaceutical ingredients (APIs), consumer healthcare products, and critical care products. The company has a global presence in over 100 countries and operates manufacturing facilities in India, the United States, and Europe. Piramal Pharma's major therapeutic areas include anti-infectives, respiratory, oncology, pain management, and critical care. The company is known for its strong research and development capabilities, which have led to the development of innovative and cost-effective generic injectables that address unmet medical needs.

52 Week Price Trend:

Piramal Pharma (PPLPHARMA), currently trading at Rs 153.05, has shown a significant increase from its 52-week low of Rs 61.62. While it has yet to reach its 52-week high of Rs 149, the stock's upward trend indicates potential for further growth. Investors may consider this positive momentum in their decision-making process, keeping in mind the potential risks and opportunities associated with the stock market.

Stratzy's MOST Analysis:

PPLPHARMA has received a BB- rating by Stratzy's MOST framework. This indicates that the stock has Medium Fundamental Risks. The framework assesses a stock's Management, Outlook, Safety, and Trend to determine its overall rating. PPLPHARMA's rating suggests that while it may have some weaknesses in these areas, it is generally considered to be a stable and reliable investment.

Fundamental and Technical information provided in this blog were last updated on 03 May, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.